Recent Findings in the Regulation of Programmed Death Ligand 1 Expression
Published 2019 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Recent Findings in the Regulation of Programmed Death Ligand 1 Expression
Authors
Keywords
-
Journal
Frontiers in Immunology
Volume 10, Issue -, Pages -
Publisher
Frontiers Media SA
Online
2019-06-14
DOI
10.3389/fimmu.2019.01337
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Translation control of the immune checkpoint in cancer and its therapeutic targeting
- (2019) Yichen Xu et al. NATURE MEDICINE
- A Clinicopathological and Prognostic Analysis of PD-L2 Expression in Surgically Resected Primary Lung Squamous Cell Carcinoma
- (2019) Taichi Matsubara et al. ANNALS OF SURGICAL ONCOLOGY
- Inhibiting PD-L1 palmitoylation enhances T-cell immune responses against tumours
- (2019) Han Yao et al. Nature Biomedical Engineering
- PD-L1 (B7-H1) Competes with the RNA Exosome to Regulate the DNA Damage Response and Can Be Targeted to Sensitize to Radiation or Chemotherapy
- (2019) Xinyi Tu et al. MOLECULAR CELL
- Correlation Between PD-L1 Expression and Clinicopathologic Features in 404 Patients with Lung Adenocarcinoma
- (2019) Peng Song et al. Interdisciplinary Sciences-Computational Life Sciences
- EGFR mutation subtypes and response to immune checkpoint blockade treatment in non-small-cell lung cancer
- (2019) K Hastings et al. ANNALS OF ONCOLOGY
- PD-L1 Induces Epithelial‐Mesenchymal Transition in Nasopharyngeal Carcinoma Cells Through Activation of the PI3K/AKT Pathway
- (2019) Zhenghua Fei et al. ONCOLOGY RESEARCH
- Circulating microRNAs associated with prolonged overall survival in lung cancer patients treated with nivolumab
- (2018) Ann Rita Halvorsen et al. ACTA ONCOLOGICA
- PD-L1 and PD-L2 Are Differentially Expressed by Macrophages or Tumor Cells in Primary Cutaneous Diffuse Large B-Cell Lymphoma, Leg Type
- (2018) Sarah Menguy et al. AMERICAN JOURNAL OF SURGICAL PATHOLOGY
- MicroRNA-140 suppresses osteosarcoma tumor growth by enhancing anti-tumor immune response and blocking mTOR signaling
- (2018) Xianglu Ji et al. BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
- FASN-TGF-β1-PD-L1 axis contributes to the development of resistance to NK cell cytotoxicity of cisplatin-resistant lung cancer cells
- (2018) Mingjing Shen et al. BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR AND CELL BIOLOGY OF LIPIDS
- Overexpressed miR-195 attenuated immune escape of diffuse large B-cell lymphoma by targeting PD-L1
- (2018) Bai He et al. BIOMEDICINE & PHARMACOTHERAPY
- Eradication of Triple-Negative Breast Cancer Cells by Targeting Glycosylated PD-L1
- (2018) Chia-Wei Li et al. CANCER CELL
- Glycans Pave the Way for Immunotherapy in Triple-Negative Breast Cancer
- (2018) Mariana Salatino et al. CANCER CELL
- Combined VEGF and PD-L1 blockade displays synergistic treatment effects in an autochthonous mouse model of small cell lung cancer
- (2018) Lydia Meder et al. CANCER RESEARCH
- The Hippo Pathway Component TAZ Promotes Immune Evasion in Human Cancer through PD-L1
- (2018) Helena J. Janse van Rensburg et al. CANCER RESEARCH
- Immunotherapy in head and neck cancers: A new challenge for immunologists, pathologists and clinicians
- (2018) Sophie Outh-Gauer et al. CANCER TREATMENT REVIEWS
- Synergy between the KEAP1/NRF2 and PI3K Pathways Drives Non-Small-Cell Lung Cancer with an Altered Immune Microenvironment
- (2018) Sarah A. Best et al. Cell Metabolism
- MiR-140 Expression Regulates Cell Proliferation and Targets PD-L1 in NSCLC
- (2018) Wei-Bin Xie et al. CELLULAR PHYSIOLOGY AND BIOCHEMISTRY
- Phase I Trial of M7824 (MSB0011359C), a Bifunctional Fusion Protein Targeting PD-L1 and TGFβ, in Advanced Solid Tumors
- (2018) Julius Strauss et al. CLINICAL CANCER RESEARCH
- Clinical and Molecular Predictors of PD-L1 Expression in Non–Small-Cell Lung Cancer: Systematic Review and Meta-analysis
- (2018) Fausto Petrelli et al. Clinical Lung Cancer
- E3 ubiquitin ligases Cbl-b and c-Cbl downregulate PD-L1 in EGFR wild-type non-small cell lung cancer
- (2018) Shuo Wang et al. FEBS LETTERS
- Regulation of Programmed Death Ligand 1 (PD-L1) Expression in Breast Cancer Cell Lines In Vitro and in Immunodeficient and Humanized Tumor Mice
- (2018) Eva-Maria Rom-Jurek et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Chemotherapy treatment is associated with altered PD-L1 expression in lung cancer patients
- (2018) Lívia Rojkó et al. JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
- Inhibition of yes-associated protein down-regulates PD-L1 (CD274) expression in human malignant pleural mesothelioma
- (2018) Ping-Chih Hsu et al. JOURNAL OF CELLULAR AND MOLECULAR MEDICINE
- The miR-3127-5p/p-STAT3 axis up-regulates PD-L1 inducing chemoresistance in non-small-cell lung cancer
- (2018) Dongfang Tang et al. JOURNAL OF CELLULAR AND MOLECULAR MEDICINE
- Potent immunogenicity in BRCA1 -mutated patients with high-grade serous ovarian carcinoma
- (2018) Ying Dai et al. JOURNAL OF CELLULAR AND MOLECULAR MEDICINE
- Cooperativity of HOXA5 and STAT3 Is Critical for HDAC8 Inhibition-Mediated Transcriptional Activation of PD-L1 in Human Melanoma Cells
- (2018) Yu Fang Wang et al. JOURNAL OF INVESTIGATIVE DERMATOLOGY
- Intrinsic and Extrinsic Regulation of PD-L2 Expression in Oncogene-Driven Non–Small Cell Lung Cancer
- (2018) Daisuke Shibahara et al. Journal of Thoracic Oncology
- Updated efficacy analysis including secondary population results for OAK: a randomized phase III study of atezolizumab vs docetaxel in patients with previously treated advanced non-small cell lung cancer
- (2018) L. Fehrenbacher et al. Journal of Thoracic Oncology
- Preliminary results for avelumab plus axitinib as first-line therapy in patients with advanced clear-cell renal-cell carcinoma (JAVELIN Renal 100): an open-label, dose-finding and dose-expansion, phase 1b trial
- (2018) Toni K Choueiri et al. LANCET ONCOLOGY
- Histone deacetylase (HDAC) inhibitor ACY241 enhances anti-tumor activities of antigen-specific central memory cytotoxic T lymphocytes against multiple myeloma and solid tumors
- (2018) Jooeun Bae et al. LEUKEMIA
- TGFβ drives immune evasion in genetically reconstituted colon cancer metastasis
- (2018) Daniele V. F. Tauriello et al. NATURE
- Clinical activity and molecular correlates of response to atezolizumab alone or in combination with bevacizumab versus sunitinib in renal cell carcinoma
- (2018) David F. McDermott et al. NATURE MEDICINE
- Atezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLC
- (2018) Mark A. Socinski et al. NEW ENGLAND JOURNAL OF MEDICINE
- Control of PD-L1 expression by miR-140/142/340/383 and oncogenic activation of the OCT4–miR-18a pathway in cervical cancer
- (2018) Peixin Dong et al. ONCOGENE
- Decitibine improve the efficiency of anti-PD-1 therapy via activating the response to IFN/PD-L1 signal of lung cancer cells
- (2018) Qi Lai et al. ONCOGENE
- Targeting the upstream transcriptional activator of PD-L1 as an alternative strategy in melanoma therapy
- (2018) Bo Zhu et al. ONCOGENE
- miR-21 depletion in macrophages promotes tumoricidal polarization and enhances PD-1 immunotherapy
- (2018) Jiajia Xi et al. ONCOGENE
- miR-375 inhibits IFN-γ-induced programmed death 1 ligand�1 surface expression in head and neck squamous cell carcinoma cells by blocking JAK2/STAT1 signaling
- (2018) Qingwei Wu et al. ONCOLOGY REPORTS
- miR-142-5p regulates CD4+ T cells in human non-small cell lung cancer through PD-L1 expression via the PTEN pathway
- (2018) Jun Wan et al. ONCOLOGY REPORTS
- Down-regulation of microRNA-135 promotes sensitivity of non-small cell lung cancer to gefitinib by targeting TRIM16
- (2018) Ning Wang et al. ONCOLOGY RESEARCH
- Safety and efficacy of anti-PD-L1 therapy in the woodchuck model of HBV infection
- (2018) Scott Balsitis et al. PLoS One
- Clinical significance of soluble programmed cell death ligand-1 (sPD-L1) in hepatocellular carcinoma patients treated with radiotherapy
- (2018) Hyun Ju Kim et al. RADIOTHERAPY AND ONCOLOGY
- Enhanced preclinical antitumor activity of M7824, a bifunctional fusion protein simultaneously targeting PD-L1 and TGF-β
- (2018) Yan Lan et al. Science Translational Medicine
- Defining and Understanding Adaptive Resistance in Cancer Immunotherapy
- (2018) Tae Kon Kim et al. TRENDS IN IMMUNOLOGY
- PD-L1 receptor expression in vulvar carcinomas is HPV-independent
- (2018) M. Choschzick et al. VIRCHOWS ARCHIV
- Oncofetal gene SALL4 reactivation by hepatitis B virus counteracts miR-200c in PD-L1-induced T cell exhaustion
- (2018) Cheng Sun et al. Nature Communications
- STT3-dependent PD-L1 accumulation on cancer stem cells promotes immune evasion
- (2018) Jung-Mao Hsu et al. Nature Communications
- Combined modality radiation therapy promotes tolerogenic myeloid cell populations and STAT3-related gene expression in head and neck cancer patients
- (2018) Sagus Sampath et al. Oncotarget
- BRCA1/2 and TP53 mutation status associates with PD-1 and PD-L1 expression in ovarian cancer
- (2018) Verena Wieser et al. Oncotarget
- YAP-Induced PD-L1 Expression Drives Immune Evasion in BRAFi-Resistant Melanoma
- (2018) Min Hwan Kim et al. Cancer Immunology Research
- Lactoferricin B reverses cisplatin resistance in head and neck squamous cell carcinoma cells through targeting PD-L1
- (2018) Pei Zhang et al. Cancer Medicine
- The IDH1 Mutation-Induced Oncometabolite, 2-Hydroxyglutarate, May Affect DNA Methylation and Expression of PD-L1 in Gliomas
- (2018) Luyan Mu et al. Frontiers in Molecular Neuroscience
- Correlation and prognostic significance of PD-L1 and P53 expression in resected primary pulmonary lymphoepithelioma-like carcinoma
- (2018) Xiang-Yang Yu et al. Journal of Thoracic Disease
- Clinical Significance of PTEN Deletion, Mutation, and Loss of PTEN Expression in De Novo Diffuse Large B-Cell Lymphoma
- (2018) Xiaoxiao Wang et al. NEOPLASIA
- PD-1/PD-L1 pathway: an adaptive immune resistance mechanism to immunogenic chemotherapy in colorectal cancer
- (2018) Magalie Dosset et al. OncoImmunology
- PD-L1 expression is regulated by both DNA methylation and NF-kB during EMT signaling in non-small cell lung carcinoma
- (2018) A. Asgarova et al. OncoImmunology
- M7824, a novel bifunctional anti-PD-L1/TGFβ Trap fusion protein, promotes anti-tumor efficacy as monotherapy and in combination with vaccine
- (2018) Karin M. Knudson et al. OncoImmunology
- PD-L2 amplification and durable disease stabilization in patient with urothelial carcinoma receiving pembrolizumab
- (2018) Saby George et al. OncoImmunology
- Dynamic change of PD-L1 expression on circulating tumor cells in advanced solid tumor patients undergoing PD-1 blockade therapy
- (2018) Chunyan Yue et al. OncoImmunology
- Increase in PD-L1 expression after pre-operative radiotherapy for soft tissue sarcoma
- (2018) Kirtesh R. Patel et al. OncoImmunology
- Efficacy and Safety of First-line Avelumab Treatment in Patients With Stage IV Metastatic Merkel Cell Carcinoma
- (2018) Sandra P. D’Angelo et al. JAMA Oncology
- Radiotherapy Upregulates Programmed Death Ligand-1 through the Pathways Downstream of Epidermal Growth Factor Receptor in Glioma
- (2018) Xing Song et al. EBioMedicine
- The Role of Immune Checkpoint Inhibitors in Classical Hodgkin Lymphoma
- (2018) Nicholas Meti et al. Cancers
- EBV up-regulates PD-L1 on the surface of primary monocytes by increasing ROS and activating TLR signaling and STAT3
- (2018) Maria Saveria Gilardini Montani et al. JOURNAL OF LEUKOCYTE BIOLOGY
- OUP accepted manuscript
- (2018) JNCI-Journal of the National Cancer Institute
- Immune marker profiling and PD-L1 expression across Non-Small Cell Lung Cancer mutations
- (2018) Maria I. Toki et al. Journal of Thoracic Oncology
- Metformin Promotes Antitumor Immunity via Endoplasmic-Reticulum-Associated Degradation of PD-L1
- (2018) Jong-Ho Cha et al. MOLECULAR CELL
- TGFβ attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells
- (2018) Sanjeev Mariathasan et al. NATURE
- PD-L2 Expression as a Potential Predictive Biomarker for the Response to Anti-PD-1 Drugs in Patients with Non-small Cell Lung Cancer
- (2018) SHINKICHI TAKAMORI et al. ANTICANCER RESEARCH
- miR-146a Controls Immune Response in the Melanoma Microenvironment
- (2018) Justin Mastroianni et al. CANCER RESEARCH
- Palmitoylation stabilizes PD-L1 to promote breast tumor growth
- (2018) Yi Yang et al. CELL RESEARCH
- DCUN1D1 facilitates tumor metastasis by activating FAK signaling and up-regulates PD-L1 in non-small-cell lung cancer
- (2018) Jing Li et al. EXPERIMENTAL CELL RESEARCH
- Polymorphism of the programmed death-ligand 1 gene is associated with its protein expression and prognosis in gastric cancer
- (2018) Yanhua Wu et al. JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY
- Phosphorylated RB Promotes Cancer Immunity by Inhibiting NF-κB Activation and PD-L1 Expression
- (2018) Xin Jin et al. MOLECULAR CELL
- HIP1R targets PD-L1 to lysosomal degradation to alter T cell–mediated cytotoxicity
- (2018) Huanbin Wang et al. Nature Chemical Biology
- Translational control of tumor immune escape via the eIF4F–STAT1–PD-L1 axis in melanoma
- (2018) Michaël Cerezo et al. NATURE MEDICINE
- PD-L1 methylation regulates PD-L1 expression and is associated with melanoma survival
- (2018) Goran Micevic et al. Pigment Cell & Melanoma Research
- Baseline β-catenin, programmed death-ligand 1 expression and tumour-infiltrating lymphocytes predict response and poor prognosis in BRAF inhibitor-treated melanoma patients
- (2017) Daniela Massi et al. EUROPEAN JOURNAL OF CANCER
- Hypoxia-induced PD-L1/PD-1 crosstalk impairs T-cell function in sleep apnoea
- (2017) Carolina Cubillos-Zapata et al. EUROPEAN RESPIRATORY JOURNAL
- Oncogenic RAS Signaling Promotes Tumor Immunoresistance by Stabilizing PD-L1 mRNA
- (2017) Matthew A. Coelho et al. IMMUNITY
- Inflammatory cytokines IL-17 and TNF-α up-regulate PD-L1 expression in human prostate and colon cancer cells
- (2017) Xun Wang et al. IMMUNOLOGY LETTERS
- PD-L1 expression as a predictive biomarker in advanced non-small-cell lung cancer: updated survival data
- (2017) Pedro N Aguiar et al. Immunotherapy
- MicroRNA-155 induction via TNF-α and IFN-γ suppresses expression of programmed death ligand-1 (PD-L1) in human primary cells
- (2017) Daniel Yee et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- STAT3 Induces Immunosuppression by Upregulating PD-1/PD-L1 in HNSCC
- (2017) L.L. Bu et al. JOURNAL OF DENTAL RESEARCH
- PD-L1 Overexpression During Endotoxin Tolerance Impairs the Adaptive Immune Response in Septic Patients via HIF1α
- (2017) José Avendaño-Ortiz et al. JOURNAL OF INFECTIOUS DISEASES
- The MLL1-H3K4me3 Axis-Mediated PD-L1 Expression and Pancreatic Cancer Immune Evasion
- (2017) Chunwan Lu et al. JNCI-Journal of the National Cancer Institute
- MA15.10 Potential Predictive Value of TP53 and KRAS Mutation Status for Response to PD-1 Blockade Immunotherapy in Lung Adenocarcinoma
- (2017) Zhong-Yi Dong et al. Journal of Thoracic Oncology
- Tumor Suppressor microRNAs Contribute to the Regulation of PD-L1 Expression in Malignant Pleural Mesothelioma
- (2017) Steven C. Kao et al. Journal of Thoracic Oncology
- Correlation between Classic Driver Oncogene Mutations in EGFR , ALK , or ROS1 and 22C3–PD-L1 ≥50% Expression in Lung Adenocarcinoma
- (2017) Deepa Rangachari et al. Journal of Thoracic Oncology
- Modulation of Hepatitis C Virus-Specific CD8 Effector T-Cell Function with Antiviral Effect in Infectious Hepatitis C Virus Coculture Model
- (2017) Keisuke Ojiro et al. JOURNAL OF VIROLOGY
- Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 study
- (2017) Michael J Overman et al. LANCET ONCOLOGY
- Safety and activity of pembrolizumab in patients with locally advanced or metastatic urothelial cancer (KEYNOTE-012): a non-randomised, open-label, phase 1b study
- (2017) Elizabeth R Plimack et al. LANCET ONCOLOGY
- PD-L1 is commonly expressed and transcriptionally regulated by STAT3 and MYC in ALK-negative anaplastic large-cell lymphoma
- (2017) V Atsaves et al. LEUKEMIA
- MUC1 inhibition leads to decrease in PD-L1 levels via upregulation of miRNAs
- (2017) A R Pyzer et al. LEUKEMIA
- Therapy-induced E-cadherin downregulation alters expression of programmed death ligand-1 in lung cancer cells
- (2017) Kenichi Suda et al. LUNG CANCER
- PIK3CA mutations as prognostic factor in squamous cell lung carcinoma
- (2017) Marc McGowan et al. LUNG CANCER
- Small-Molecule Sigma1 Modulator Induces Autophagic Degradation of PD-L1
- (2017) Christina M. Maher et al. MOLECULAR CANCER RESEARCH
- Chemotherapy induces tumor immune evasion by upregulation of programmed cell death ligand 1 expression in bone marrow stromal cells
- (2017) Mengqi Yang et al. Molecular Oncology
- Identification of CMTM6 and CMTM4 as PD-L1 protein regulators
- (2017) Riccardo Mezzadra et al. NATURE
- Cyclin D–CDK4 kinase destabilizes PD-L1 via cullin 3–SPOP to control cancer immune surveillance
- (2017) Jinfang Zhang et al. NATURE
- Palmitoylation-dependent activation of MC1R prevents melanomagenesis
- (2017) Shuyang Chen et al. NATURE
- CMTM6 maintains the expression of PD-L1 and regulates anti-tumour immunity
- (2017) Marian L. Burr et al. NATURE
- Correlation of immune phenotype with IDH mutation in diffuse glioma
- (2017) Anna Sophie Berghoff et al. NEURO-ONCOLOGY
- Durvalumab after Chemoradiotherapy in Stage III Non–Small-Cell Lung Cancer
- (2017) Scott J. Antonia et al. NEW ENGLAND JOURNAL OF MEDICINE
- Tumor cell-derived lactate induces TAZ-dependent upregulation of PD-L1 through GPR81 in human lung cancer cells
- (2017) J Feng et al. ONCOGENE
- BIN1 reverses PD-L1-mediated immune escape by inactivating the c-MYC and EGFR/MAPK signaling pathways in non-small cell lung cancer
- (2017) J Wang et al. ONCOGENE
- MUC1-C integrates PD-L1 induction with repression of immune effectors in non-small-cell lung cancer
- (2017) A Bouillez et al. ONCOGENE
- FDA Approval Summary: Pembrolizumab for the Treatment of Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma with Disease Progression on or After Platinum‐Containing Chemotherapy
- (2017) Erin Larkins et al. ONCOLOGIST
- The JAK/STAT pathway is involved in the upregulation of PD-L1 expression in pancreatic cancer cell lines
- (2017) Toshifumi Doi et al. ONCOLOGY REPORTS
- A study of PD-L1 expression in KRAS mutant non-small cell lung cancer cell lines exposed to relevant targeted treatments
- (2017) Anna Minchom et al. PLoS One
- A Trp53fl/flPtenfl/fl mouse model of undifferentiated pleomorphic sarcoma mediated by adeno-Cre injection and in vivo bioluminescence imaging
- (2017) Marisa R. Buchakjian et al. PLoS One
- Membrane targeting of inhibitory Smads through palmitoylation controls TGF-β/BMP signaling
- (2017) Wenqing Li et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Medicinal Chemistry Insights into Novel HDAC Inhibitors: An Updated Patent Review (2012-2016)
- (2017) Peng Zhan et al. Recent Patents on Anti-Cancer Drug Discovery
- Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade
- (2017) Dung T. Le et al. SCIENCE
- Kaposi’s Sarcoma-Associated Herpesvirus Increases PD-L1 and Proinflammatory Cytokine Expression in Human Monocytes
- (2017) Kurtis M. Host et al. mBio
- PD-L1 is an activation-independent marker of brown adipocytes
- (2017) Jessica R. Ingram et al. Nature Communications
- DNA double-strand break repair pathway regulates PD-L1 expression in cancer cells
- (2017) Hiro Sato et al. Nature Communications
- CDK4/6 Inhibitors Increase PD-L1 Expression
- (2017) Cancer Discovery
- Changes in programmed death-ligand 1 expression during cisplatin treatment in patients with head and neck squamous cell carcinoma
- (2017) Chan-Young Ock et al. Oncotarget
- Clinicopathologic implications of the miR-197/PD-L1 axis in oral squamous cell carcinoma
- (2017) Hyein Ahn et al. Oncotarget
- Radiation alters PD-L1/NKG2D ligand levels in lung cancer cells and leads to immune escape from NK cell cytotoxicity via IL-6-MEK/Erk signaling pathway
- (2017) Ming Jing Shen et al. Oncotarget
- A regulatory role for the co-chaperone FKBP51s in PD-L1 expression in glioma
- (2017) Paolo D'Arrigo et al. Oncotarget
- TUSC2 downregulates PD-L1 expression in non-small cell lung cancer (NSCLC)
- (2017) Xiaobo Cao et al. Oncotarget
- PD-L1 promoter methylation mediates the resistance response to anti-PD-1 therapy in NSCLC patients with EGFR-TKI resistance
- (2017) Yan Zhang et al. Oncotarget
- PD-L1 (CD274) and PD-L2 (PDCD1LG2) promoter methylation is associated with HPV infection and transcriptional repression in head and neck squamous cell carcinomas
- (2017) Alina Franzen et al. Oncotarget
- The miR-25-93-106b cluster regulates tumor metastasis and immune evasion via modulation of CXCL12 and PD-L1
- (2017) Michele Cioffi et al. Oncotarget
- miR-217 inhibits laryngeal cancer metastasis by repressing AEG-1 and PD-L1 expression
- (2017) Susheng Miao et al. Oncotarget
- PD-L1 up-regulation in melanoma increases disease aggressiveness and is mediated through miR-17-5p
- (2017) Valentina Audrito et al. Oncotarget
- HDAC inhibitors enhance the immunotherapy response of melanoma cells
- (2017) Laurence Booth et al. Oncotarget
- YAP regulates PD-L1 expression in human NSCLC cells
- (2017) Jinbai Miao et al. Oncotarget
- BET-Bromodomain Inhibitors Engage the Host Immune System and Regulate Expression of the Immune Checkpoint Ligand PD-L1
- (2017) Simon J. Hogg et al. Cell Reports
- Interferon Receptor Signaling Pathways Regulating PD-L1 and PD-L2 Expression
- (2017) Angel Garcia-Diaz et al. Cell Reports
- Tri-methylation of H3K79 is decreased in TGF-β1-induced epithelial-to-mesenchymal transition in lung cancer
- (2017) Emilie Evanno et al. Clinical Epigenetics
- The MLL1-H3K4me3 Axis-Mediated PD-L1 Expression and Pancreatic Cancer Immune Evasion
- (2017) Chunwan Lu et al. JNCI-Journal of the National Cancer Institute
- Temporally Distinct PD-L1 Expression by Tumor and Host Cells Contributes to Immune Escape
- (2017) Takuro Noguchi et al. Cancer Immunology Research
- Cisplatin Alters Antitumor Immunity and Synergizes with PD-1/PD-L1 Inhibition in Head and Neck Squamous Cell Carcinoma
- (2017) Linda Tran et al. Cancer Immunology Research
- A combination of anti-PD-L1 mAb plus Lm-LLO-E6 vaccine efficiently suppresses tumor growth and metastasis in HPV-infected cancers
- (2017) Po-Lin Lin et al. Cancer Medicine
- CD80 Expressed by CD8+ T Cells Contributes to PD-L1-Induced Apoptosis of Activated CD8+ T Cells
- (2017) Meagan R. Rollins et al. Journal of Immunology Research
- Local High-Dose Radiotherapy Induces Systemic Immunomodulating Effects of Potential Therapeutic Relevance in Oligometastatic Breast Cancer
- (2017) Elena Muraro et al. Frontiers in Immunology
- Identifying Regulatory Posttranslational Modifications of PD-L1: A Focus on Monoubiquitinaton
- (2017) Henrick Horita et al. NEOPLASIA
- Ionizing radiation sensitizes tumors to PD-L1 immune checkpoint blockade in orthotopic murine head and neck squamous cell carcinoma
- (2017) Ayman Oweida et al. OncoImmunology
- EGFR mutation correlates with uninflamed phenotype and weak immunogenicity, causing impaired response to PD-1 blockade in non-small cell lung cancer
- (2017) Zhong-Yi Dong et al. OncoImmunology
- Host immune response index in gastric cancer identified by comprehensive analyses of tumor immunity
- (2017) Charny Park et al. OncoImmunology
- Composite biomarkers defined by multiparametric immunofluorescence analysis identify ALK-positive adenocarcinoma as a potential target for immunotherapy
- (2017) Hélène Roussel et al. OncoImmunology
- PD-L1 (CD274) copy number gain, expression, and immune cell infiltration as candidate predictors for response to immune checkpoint inhibitors in soft-tissue sarcoma
- (2017) Jan Budczies et al. OncoImmunology
- Efficacy and Safety of Durvalumab in Locally Advanced or Metastatic Urothelial Carcinoma
- (2017) Thomas Powles et al. JAMA Oncology
- Neoadjuvant chemotherapy (NACT) increases immune infiltration and programmed death-ligand 1 (PD-L1) expression in epithelial ovarian cancer (EOC)
- (2016) S J L Mesnage et al. ANNALS OF ONCOLOGY
- Genetic basis of PD-L1 overexpression in diffuse large B-cell lymphomas
- (2016) K. Georgiou et al. BLOOD
- A Novel Link between Inflammation and Cancer
- (2016) Yenkel Grinberg-Bleyer et al. CANCER CELL
- YAP/TAZ at the Roots of Cancer
- (2016) Francesca Zanconato et al. CANCER CELL
- Deubiquitination and Stabilization of PD-L1 by CSN5
- (2016) Seung-Oe Lim et al. CANCER CELL
- A polymorphism in the promoter region of PD-L1 serves as a binding-site for SP1 and is associated with PD-L1 overexpression and increased occurrence of gastric cancer
- (2016) Li-Hua Tao et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Upregulation of programmed cell death ligand 1 promotes resistance response in non-small-cell lung cancer patients treated with neo-adjuvant chemotherapy
- (2016) Panpan Zhang et al. CANCER SCIENCE
- Genomic Amplification of CD274 (PD-L1) in Small-Cell Lung Cancer
- (2016) Julie George et al. CLINICAL CANCER RESEARCH
- HDAC Inhibitors Enhance T-Cell Chemokine Expression and Augment Response to PD-1 Immunotherapy in Lung Adenocarcinoma
- (2016) Hong Zheng et al. CLINICAL CANCER RESEARCH
- PD-L1 expression in cancer patients receiving anti PD-1/PD-L1 antibodies: A systematic review and meta-analysis
- (2016) Sara Gandini et al. CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY
- PD‐L1 blockade enhances response of pancreatic ductal adenocarcinoma to radiotherapy
- (2016) Abul Azad et al. EMBO Molecular Medicine
- Renal Cell Carcinoma Programmed Death-ligand 1, a New Direct Target of Hypoxia-inducible Factor-2 Alpha, is Regulated by von Hippel–Lindau Gene Mutation Status
- (2016) Yosra Messai et al. EUROPEAN UROLOGY
- Pan-cancer analysis of copy number changes in programmed death-ligand 1 (PD-L1, CD274) - associations with gene expression, mutational load, and survival
- (2016) Jan Budczies et al. GENES CHROMOSOMES & CANCER
- PD-L1 expression is regulated by hypoxia inducible factor in clear cell renal cell carcinoma
- (2016) Melanie Ruf et al. INTERNATIONAL JOURNAL OF CANCER
- Drug resistance originating from a TGF-β/FGF-2-driven epithelial-to-mesenchymal transition and its reversion in human lung adenocarcinoma cell lines harboring an EGFR mutation
- (2016) RYOTA KURIMOTO et al. INTERNATIONAL JOURNAL OF ONCOLOGY
- The EGFR pathway is involved in the regulation of PD-L1 expression via the IL-6/JAK/STAT3 signaling pathway in EGFR-mutated non-small cell lung cancer
- (2016) Nan Zhang et al. INTERNATIONAL JOURNAL OF ONCOLOGY
- MiR-16 regulates mouse peritoneal macrophage polarization and affects T-cell activation
- (2016) Xiaoqin Jia et al. JOURNAL OF CELLULAR AND MOLECULAR MEDICINE
- PD-L1 and PD-L2 Genetic Alterations Define Classical Hodgkin Lymphoma and Predict Outcome
- (2016) Margaretha G.M. Roemer et al. JOURNAL OF CLINICAL ONCOLOGY
- Antitumor Activity of Pembrolizumab in Biomarker-Unselected Patients With Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma: Results From the Phase Ib KEYNOTE-012 Expansion Cohort
- (2016) Laura Q.M. Chow et al. JOURNAL OF CLINICAL ONCOLOGY
- PD-L1 is upregulated by EBV-driven LMP1 through NF-κB pathway and correlates with poor prognosis in natural killer/T-cell lymphoma
- (2016) Xi-wen Bi et al. Journal of Hematology & Oncology
- PD-L1 Is Upregulated by Simultaneous Amplification of the PD-L1 and JAK2 Genes in Non–Small Cell Lung Cancer
- (2016) Seiichi Ikeda et al. Journal of Thoracic Oncology
- PD-L1 (CD274) promoter methylation predicts survival in patients with acute myeloid leukemia
- (2016) D Goltz et al. LEUKEMIA
- Clinicopathological and prognostic significance of programmed cell death ligand-1 expression in lung adenocarcinoma and its relationship with p53 status
- (2016) Yoon Jin Cha et al. LUNG CANCER
- Essential role of HDAC6 in the regulation of PD-L1 in melanoma
- (2016) M. Lienlaf et al. Molecular Oncology
- Aberrant PD-L1 expression through 3′-UTR disruption in multiple cancers
- (2016) Keisuke Kataoka et al. NATURE
- Elevation of Alanine Aminotransferase Activity Occurs after Activation of the Cell-Death Signaling Initiated by Pattern-Recognition Receptors but before Activation of Cytolytic Effectors in NK or CD8+ T Cells in the Liver During Acute HCV Infection
- (2016) Youkyung H. Choi et al. PLoS One
- MYC regulates the antitumor immune response through CD47 and PD-L1
- (2016) S. C. Casey et al. SCIENCE
- Cdk5 disruption attenuates tumor PD-L1 expression and promotes antitumor immunity
- (2016) R. D. Dorand et al. SCIENCE
- CXCL12 expression and PD-L1 expression serve as prognostic biomarkers in HCC and are induced by hypoxia
- (2016) Alexander Semaan et al. VIRCHOWS ARCHIV
- Glycosylation and stabilization of programmed death ligand-1 suppresses T-cell activity
- (2016) Chia-Wei Li et al. Nature Communications
- miR-424(322) reverses chemoresistance via T-cell immune response activation by blocking the PD-L1 immune checkpoint
- (2016) Shaohua Xu et al. Nature Communications
- Nivolumab Doubles Survival for Patients with HNSCC
- (2016) Cancer Discovery
- PD-L1 expression in tonsillar cancer is associated with human papillomavirus positivity and improved survival: implications for anti-PD1 clinical trials
- (2016) Angela M Hong et al. Oncotarget
- The tumor suppressor miR-138-5p targets PD-L1 in colorectal cancer
- (2016) Lian Zhao et al. Oncotarget
- PD-L1 promoter methylation is a prognostic biomarker for biochemical recurrence-free survival in prostate cancer patients following radical prostatectomy
- (2016) Heidrun Gevensleben et al. Oncotarget
- Association and prognostic significance of BRCA1/2-mutation status with neoantigen load, number of tumor-infiltrating lymphocytes and expression of PD-1/PD-L1 in high grade serous ovarian cancer
- (2016) Kyle C. Strickland et al. Oncotarget
- BET Bromodomain Inhibition Promotes Anti-tumor Immunity by Suppressing PD-L1 Expression
- (2016) Hengrui Zhu et al. Cell Reports
- TGFβ-dependent expression of PD-1 and PD-L1 controls CD8+ T cell anergy in transplant tolerance
- (2016) Marije Baas et al. eLife
- Myeloma Drug Resistance Induced by Binding of Myeloma B7-H1 (PD-L1) to PD-1
- (2016) M. Ishibashi et al. Cancer Immunology Research
- PD-L1 (CD274) promoter methylation predicts survival in colorectal cancer patients
- (2016) Diane Goltz et al. OncoImmunology
- Regulation of cytotoxic T-cell responses by p53 in cancer
- (2016) Mitchell W. Braun et al. Translational Cancer Research
- 5-Fluorouracil upregulates cell surface B7-H1 (PD-L1) expression in gastrointestinal cancers
- (2016) Lauren Van Der Kraak et al. Journal for ImmunoTherapy of Cancer
- Increased CD86 but Not CD80 and PD-L1 Expression on Liver CD68+ Cells during Chronic HBV Infection
- (2016) Elias A. Said et al. PLoS One
- Elevated Cellular PD1/PD-L1 Expression Confers Acquired Resistance to Cisplatin in Small Cell Lung Cancer Cells
- (2016) Fei Yan et al. PLoS One
- TLR3-Induced Maturation of Murine Dendritic Cells Regulates CTL Responses by Modulating PD-L1 Trafficking
- (2016) Aditi Varthaman et al. PLoS One
- RAS–Mitogen-Activated Protein Kinase Signal Is Required for Enhanced PD-L1 Expression in Human Lung Cancers
- (2016) Hidetoshi Sumimoto et al. PLoS One
- miR-24, miR-30b and miR-142-3p interfere with antigen processing and presentation by primary macrophages and dendritic cells
- (2016) Afsar Raza Naqvi et al. Scientific Reports
- PD-L1 copy number gain in nonsmall-cell lung cancer defines a new subset of patients for anti PD-L1 therapy
- (2015) T. Goldmann et al. ANNALS OF ONCOLOGY
- Regulation of PD-L1: a novel role of pro-survival signalling in cancer
- (2015) J. Chen et al. ANNALS OF ONCOLOGY
- EGFR-TKI down-regulates PD-L1 in EGFR mutant NSCLC through inhibiting NF-κB
- (2015) Kailong Lin et al. BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
- IFN-γ from lymphocytes induces PD-L1 expression and promotes progression of ovarian cancer
- (2015) K Abiko et al. BRITISH JOURNAL OF CANCER
- An HPV-E6/E7 immunotherapy plus PD-1 checkpoint inhibition results in tumor regression and reduction in PD-L1 expression
- (2015) A E Rice et al. CANCER GENE THERAPY
- TLR3 triggering regulates PD-L1 (CD274) expression in human neuroblastoma cells
- (2015) Marianne Boes et al. CANCER LETTERS
- Chemotherapy Induces Programmed Cell Death-Ligand 1 Overexpression via the Nuclear Factor- B to Foster an Immunosuppressive Tumor Microenvironment in Ovarian Cancer
- (2015) J. Peng et al. CANCER RESEARCH
- Identification of the Cell-Intrinsic and -Extrinsic Pathways Downstream of EGFR and IFN That Induce PD-L1 Expression in Head and Neck Cancer
- (2015) F. Concha-Benavente et al. CANCER RESEARCH
- Control of PD-L1 Expression by Oncogenic Activation of the AKT–mTOR Pathway in Non–Small Cell Lung Cancer
- (2015) Kristin J. Lastwika et al. CANCER RESEARCH
- Tumor suppressor miR-34a targets PD-L1 and functions as a potential immunotherapeutic target in acute myeloid leukemia
- (2015) Xi Wang et al. CELLULAR SIGNALLING
- Induction of PD-L1 Expression by the EML4-ALK Oncoprotein and Downstream Signaling Pathways in Non-Small Cell Lung Cancer
- (2015) K. Ota et al. CLINICAL CANCER RESEARCH
- The BRAF and MEK Inhibitors Dabrafenib and Trametinib: Effects on Immune Function and in Combination with Immunomodulatory Antibodies Targeting PD-1, PD-L1, and CTLA-4
- (2015) L. Liu et al. CLINICAL CANCER RESEARCH
- RAS/MAPK Activation Is Associated with Reduced Tumor-Infiltrating Lymphocytes in Triple-Negative Breast Cancer: Therapeutic Cooperation Between MEK and PD-1/PD-L1 Immune Checkpoint Inhibitors
- (2015) S. Loi et al. CLINICAL CANCER RESEARCH
- Anti–PD-1/PD-L1 therapy of human cancer: past, present, and future
- (2015) Lieping Chen et al. JOURNAL OF CLINICAL INVESTIGATION
- Nivolumab for Metastatic Renal Cell Carcinoma: Results of a Randomized Phase II Trial
- (2015) Robert J. Motzer et al. JOURNAL OF CLINICAL ONCOLOGY
- Increase of PD-L1 expressing B-precursor ALL cells in a patient resistant to the CD19/CD3-bispecific T cell engager antibody blinatumomab
- (2015) Thomas Köhnke et al. Journal of Hematology & Oncology
- PDL1 Regulation by p53 via miR-34
- (2015) Maria Angelica Cortez et al. JNCI-Journal of the National Cancer Institute
- Upregulation of PD-L1 by EGFR Activation Mediates the Immune Escape in EGFR-Driven NSCLC: Implication for Optional Immune Targeted Therapy for NSCLC Patients with EGFR Mutation
- (2015) Nan Chen et al. Journal of Thoracic Oncology
- Combined Trabectedin and anti-PD1 antibody produces a synergistic antitumor effect in a murine model of ovarian cancer
- (2015) Zhiqiang Guo et al. Journal of Translational Medicine
- Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial
- (2015) Jeffrey S Weber et al. LANCET ONCOLOGY
- The Clinical Relevance of the miR-197/CKS1B/STAT3-mediated PD-L1 Network in Chemoresistant Non-small-cell Lung Cancer
- (2015) Yu Fujita et al. MOLECULAR THERAPY
- Brca2 Deficiency Leads to T Cell Loss and Immune Dysfunction
- (2015) Jun-hyeon Jeong et al. MOLECULES AND CELLS
- Immunosuppressive plasma cells impede T-cell-dependent immunogenic chemotherapy
- (2015) Shabnam Shalapour et al. NATURE
- Nivolumab in Previously Untreated Melanoma without BRAF Mutation
- (2015) Caroline Robert et al. NEW ENGLAND JOURNAL OF MEDICINE
- PD-1 Blockade in Tumors with Mismatch-Repair Deficiency
- (2015) Dung T. Le et al. NEW ENGLAND JOURNAL OF MEDICINE
- Pembrolizumab for the Treatment of Non–Small-Cell Lung Cancer
- (2015) Edward B. Garon et al. NEW ENGLAND JOURNAL OF MEDICINE
- PD-1 Blockade with Nivolumab in Relapsed or Refractory Hodgkin's Lymphoma
- (2015) Stephen M. Ansell et al. NEW ENGLAND JOURNAL OF MEDICINE
- Control of signaling-mediated clearance of apoptotic cells by the tumor suppressor p53
- (2015) K. W. Yoon et al. SCIENCE
- IL-27 induces the expression of IDO and PD-L1 in human cancer cells
- (2015) Grazia Carbotti et al. Oncotarget
- PDL1 Regulation by p53 via miR-34
- (2015) Maria Angelica Cortez et al. JNCI-Journal of the National Cancer Institute
- HDAC Inhibition Upregulates PD-1 Ligands in Melanoma and Augments Immunotherapy with PD-1 Blockade
- (2015) D. M. Woods et al. Cancer Immunology Research
- Augmenting Antitumor Immune Responses with Epigenetic Modifying Agents
- (2015) Erika Héninger et al. Frontiers in Immunology
- EML4-ALK enhances programmed cell death-ligand 1 expression in pulmonary adenocarcinoma via hypoxia-inducible factor (HIF)-1α and STAT3
- (2015) Jaemoon Koh et al. OncoImmunology
- Interferon-γ-induced activation of JAK1 and JAK2 suppresses tumor cell susceptibility to NK cells through upregulation of PD-L1 expression
- (2015) Roberto Bellucci et al. OncoImmunology
- Exogenous Restoration of TUSC2 Expression Induces Responsiveness to Erlotinib in Wildtype Epidermal Growth Factor Receptor (EGFR) Lung Cancer Cells through Context Specific Pathways Resulting in Enhanced Therapeutic Efficacy
- (2015) Bingbing Dai et al. PLoS One
- Inducible but Not Constitutive Expression of PD-L1 in Human Melanoma Cells Is Dependent on Activation of NF-κB
- (2015) Kavitha Gowrishankar et al. PLoS One
- Alterations of immune response of non-small cell lung cancer with Azacytidine
- (2015) John Wrangle et al. Oncotarget
- EBV-driven LMP1 and IFN-γ up-regulate PD-L1 in nasopharyngeal carcinoma: Implications for oncotargeted therapy
- (2015) Wenfeng Fang et al. Oncotarget
- Association of PD-L1 overexpression with activating EGFR mutations in surgically resected nonsmall-cell lung cancer
- (2014) K. Azuma et al. ANNALS OF ONCOLOGY
- Loss of Lkb1 and Pten Leads to Lung Squamous Cell Carcinoma with Elevated PD-L1 Expression
- (2014) Chunxiao Xu et al. CANCER CELL
- Acquired Resistance to Fractionated Radiotherapy Can Be Overcome by Concurrent PD-L1 Blockade
- (2014) S. J. Dovedi et al. CANCER RESEARCH
- Effects of MAPK and PI3K Pathways on PD-L1 Expression in Melanoma
- (2014) M. Atefi et al. CLINICAL CANCER RESEARCH
- MiR-20b, -21, and -130b inhibit PTEN expression resulting in B7-H1 over-expression in advanced colorectal cancer
- (2014) Jianjie Zhu et al. HUMAN IMMUNOLOGY
- Paclitaxel Induced B7-H1 Expression in Cancer Cells via the MAPK Pathway
- (2014) Wenrong Gong et al. JOURNAL OF CHEMOTHERAPY
- Irradiation and anti–PD-L1 treatment synergistically promote antitumor immunity in mice
- (2014) Liufu Deng et al. JOURNAL OF CLINICAL INVESTIGATION
- PD-L1 is a novel direct target of HIF-1α, and its blockade under hypoxia enhanced MDSC-mediated T cell activation
- (2014) Muhammad Zaeem Noman et al. JOURNAL OF EXPERIMENTAL MEDICINE
- MicroRNA-513 Regulates B7-H1 Translation and Is Involved in IFN- -Induced B7-H1 Expression in Cholangiocytes
- (2014) A.-Y. Gong et al. JOURNAL OF IMMUNOLOGY
- TLR4 Activation Enhances the PD-L1–Mediated Tolerogenic Capacity of Colonic CD90+Stromal Cells
- (2014) Ellen J. Beswick et al. JOURNAL OF IMMUNOLOGY
- Synergistic effects of IL-4 and TNFα on the induction of B7-H1 in renal cell carcinoma cells inhibiting allogeneic T cell proliferation
- (2014) Dagmar Quandt et al. Journal of Translational Medicine
- HIV-1 Tat Protein Induces PD-L1 (B7-H1) Expression on Dendritic Cells through Tumor Necrosis Factor Alpha- and Toll-Like Receptor 4-Mediated Mechanisms
- (2014) R. Planes et al. JOURNAL OF VIROLOGY
- Comprehensive molecular characterization of gastric adenocarcinoma
- (2014) Adam J. Bass et al. NATURE
- MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer
- (2014) Thomas Powles et al. NATURE
- Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients
- (2014) Roy S. Herbst et al. NATURE
- Histone deacetylases and their inhibitors in cancer, neurological diseases and immune disorders
- (2014) Katrina J. Falkenberg et al. NATURE REVIEWS DRUG DISCOVERY
- Eradication of metastatic mouse cancers resistant to immune checkpoint blockade by suppression of myeloid-derived cells
- (2014) K. Kim et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- HIF-1α and HIF-2α are critically involved in hypoxia-induced lipid accumulation in hepatocytes through reducing PGC-1α-mediated fatty acid β-oxidation
- (2014) Yanlong Liu et al. TOXICOLOGY LETTERS
- Metastasis is regulated via microRNA-200/ZEB1 axis control of tumour cell PD-L1 expression and intratumoral immunosuppression
- (2014) Limo Chen et al. Nature Communications
- PD-L1 Blockade Maintains Irradiation-Mediated Antitumor Immunity
- (2014) Cancer Discovery
- PD-L1 Expression in Triple-Negative Breast Cancer
- (2014) E. A. Mittendorf et al. Cancer Immunology Research
- Vascular Normalization as an Emerging Strategy to Enhance Cancer Immunotherapy
- (2013) Y. Huang et al. CANCER RESEARCH
- A Mechanism of Hypoxia-Mediated Escape from Adaptive Immunity in Cancer Cells
- (2013) I. B. Barsoum et al. CANCER RESEARCH
- Evidence for a Role of the PD-1:PD-L1 Pathway in Immune Resistance of HPV-Associated Head and Neck Squamous Cell Carcinoma
- (2013) S. Lyford-Pike et al. CANCER RESEARCH
- A miR-570 binding site polymorphism in the B7-H1 gene is associated with the risk of gastric adenocarcinoma
- (2013) Weipeng Wang et al. HUMAN GENETICS
- Increased expression of programmed death (PD)-1 and its ligand PD-L1 correlates with impaired cell-mediated immunity in high-risk human papillomavirus-related cervical intraepithelial neoplasia
- (2013) Wen Yang et al. IMMUNOLOGY
- Structure and Interactions of the Human Programmed Cell Death 1 Receptor
- (2013) Xiaoxiao Cheng et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Expression of PD-L1, PD-L2, PD-1 and CTLA4 in myelodysplastic syndromes is enhanced by treatment with hypomethylating agents
- (2013) H Yang et al. LEUKEMIA
- STAT3 and HIF1α cooperatively activate HIF1 target genes in MDA-MB-231 and RCC4 cells
- (2013) M R Pawlus et al. ONCOGENE
- PTEN Loss Increases PD-L1 Protein Expression and Affects the Correlation between PD-L1 Expression and Clinical Parameters in Colorectal Cancer
- (2013) Minmin Song et al. PLoS One
- IFN-γ-Stimulated Neutrophils Suppress Lymphocyte Proliferation through Expression of PD-L1
- (2013) Stan de Kleijn et al. PLoS One
- Dendritic cell co-stimulatory and co-inhibitory markers in chronic HCV: An Egyptian study
- (2013) Hanan Fouad WORLD JOURNAL OF GASTROENTEROLOGY
- N-Linked Protein Glycosylation in the Endoplasmic Reticulum
- (2013) J. Breitling et al. Cold Spring Harbor Perspectives in Biology
- PD-L1 Expression in the Merkel Cell Carcinoma Microenvironment: Association with Inflammation, Merkel Cell Polyomavirus, and Overall Survival
- (2013) E. J. Lipson et al. Cancer Immunology Research
- MYC on the Path to Cancer
- (2012) Chi V. Dang CELL
- Constitutive AP-1 Activity and EBV Infection Induce PD-L1 in Hodgkin Lymphomas and Posttransplant Lymphoproliferative Disorders: Implications for Targeted Therapy
- (2012) M. R. Green et al. CLINICAL CANCER RESEARCH
- The Activation of MAPK in Melanoma Cells Resistant to BRAF Inhibition Promotes PD-L1 Expression That Is Reversible by MEK and PI3K Inhibition
- (2012) X. Jiang et al. CLINICAL CANCER RESEARCH
- EBV stimulates TLR- and autophagy-dependent pathways and impairs maturation in plasmacytoid dendritic cells: Implications for viral immune escape
- (2012) Martina Severa et al. EUROPEAN JOURNAL OF IMMUNOLOGY
- Effect of miR-513a-5p on etoposide-stimulating B7-H1 expression in retinoblastoma cells
- (2012) Li Wu et al. Journal of Huazhong University of Science and Technology-Medical Sciences
- Class I Histone Deacetylase Inhibitor Entinostat Suppresses Regulatory T Cells and Enhances Immunotherapies in Renal and Prostate Cancer Models
- (2012) Li Shen et al. PLoS One
- Vascular normalizing doses of antiangiogenic treatment reprogram the immunosuppressive tumor microenvironment and enhance immunotherapy
- (2012) Y. Huang et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Colocalization of Inflammatory Response with B7-H1 Expression in Human Melanocytic Lesions Supports an Adaptive Resistance Mechanism of Immune Escape
- (2012) J. M. Taube et al. Science Translational Medicine
- Hypoxia Induces Escape from Innate Immunity in Cancer Cells via Increased Expression of ADAM10: Role of Nitric Oxide
- (2011) I. B. Barsoum et al. CANCER RESEARCH
- Mechanisms and principles of N-linked protein glycosylation
- (2011) Flavio Schwarz et al. CURRENT OPINION IN STRUCTURAL BIOLOGY
- A frequent somatic mutation in CD274 3′-UTR leads to protein over-expression in gastric cancer by disrupting miR-570 binding
- (2011) Weipeng Wang et al. HUMAN MUTATION
- p53 regulates epithelial–mesenchymal transition through microRNAs targeting ZEB1 and ZEB2
- (2011) Taewan Kim et al. JOURNAL OF EXPERIMENTAL MEDICINE
- HIV-Mediated Phosphatidylinositol 3-Kinase/Serine-Threonine Kinase Activation in APCs Leads to Programmed Death-1 Ligand Upregulation and Suppression of HIV-Specific CD8 T Cells
- (2011) K. Muthumani et al. JOURNAL OF IMMUNOLOGY
- Integrative analysis reveals selective 9p24.1 amplification, increased PD-1 ligand expression, and further induction via JAK2 in nodular sclerosing Hodgkin lymphoma and primary mediastinal large B-cell lymphoma
- (2010) M. R. Green et al. BLOOD
- Interferon- and tumor necrosis factor- induce an immunoinhibitory molecule, B7-H1, via nuclear factor- B activation in blasts in myelodysplastic syndromes
- (2010) A. Kondo et al. BLOOD
- Tumor cell expression of programmed cell death-1 ligand 1 is a prognostic factor for malignant melanoma
- (2010) Ryosuke Hino et al. CANCER
- Increased PD-L1 expression and PD-L1/CD86 ratio on dendritic cells were associated with impaired dendritic cells function in HCV infection
- (2010) Tao Shen et al. JOURNAL OF MEDICAL VIROLOGY
- High expression of PD-L1 in lung cancer may contribute to poor prognosis and tumor cells immune escape through suppressing tumor infiltrating dendritic cells maturation
- (2010) Chuan-Yong Mu et al. MEDICAL ONCOLOGY
- Upregulation of PD-L1 on monocytes and dendritic cells by HIV-1 derived TLR ligands
- (2009) Angela Meier et al. AIDS
- B7-H1 expression is regulated by MEK/ERK signaling pathway in anaplastic large cell lymphoma and Hodgkin lymphoma
- (2009) Ryo Yamamoto et al. CANCER SCIENCE
- MicroRNAs: Target Recognition and Regulatory Functions
- (2009) David P. Bartel CELL
- TLR3-Stimulated Dendritic Cells Up-regulate B7-H1 Expression and Influence the Magnitude of CD8 T Cell Responses to Tumor Vaccination
- (2009) V. Pulko et al. JOURNAL OF IMMUNOLOGY
- Cryptosporidium parvumInduces B7‐H1 Expression in Cholangiocytes by Down‐Regulating MicroRNA‐513
- (2009) Ai‐Yu Gong et al. JOURNAL OF INFECTIOUS DISEASES
- Mechanisms of FUS1/TUSC2 deficiency in mesothelioma and its tumorigenic transcriptional effects
- (2009) Alla V Ivanova et al. Molecular Cancer
- PD-1 and Its Ligands in Tolerance and Immunity
- (2008) Mary E. Keir et al. Annual Review of Immunology
- TLR4 Signaling Induces B7-H1 Expression Through MAPK Pathways in Bladder Cancer Cells
- (2008) Yigang Qian et al. CANCER INVESTIGATION
- Epigenetics in Cancer
- (2008) Manel Esteller NEW ENGLAND JOURNAL OF MEDICINE
- Oncogenic kinase NPM/ALK induces through STAT3 expression of immunosuppressive protein CD274 (PD-L1, B7-H1)
- (2008) M. Marzec et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Chemopreventive agents induce programmed death-1-ligand 1 (PD-L1) surface expression in breast cancer cells and promote PD-L1-mediated T cell apoptosis
- (2007) Ping Zhang et al. MOLECULAR IMMUNOLOGY
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started